Registered report: The CD47-signal regulated protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Author:
Affiliation:
1. Noble Life Sciences, Gaithersburg, United States
2. Harvard Stem Cell Institute, Cambridge, United States
3. University of Virginia, Charlottesville, United States
Abstract
Funder
Laura and John Arnold Foundation
Publisher
eLife Sciences Publications, Ltd
Subject
General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience
Link
https://cdn.elifesciences.org/articles/04586/elife-04586-v1.pdf
Reference17 articles.
1. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells;Chan;Proceedings of the National Academy of Sciences of USA,2009
2. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia;Chao;Cancer Research,2010a
3. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma;Chao;Cell,2010b
4. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy;Demaria;Clinical Cancer Research,2001
5. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma;Edris;Proceedings of the National Academy of Sciences of USA,2012
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Tolerating CD47;Clinical and Translational Medicine;2024-02
2. Challenges for assessing replicability in preclinical cancer biology;eLife;2021-12-07
3. IL2RG ‐deficient minipigs generated via CRISPR/Cas9 technology support the growth of human melanoma‐derived tumours;Cell Proliferation;2020-09
4. TSP1‐CD47‐SIRPα signaling facilitates the development of endometriosis by mediating the survival of ectopic endometrium;American Journal of Reproductive Immunology;2020-04-18
5. Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors;eLife;2017-01-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3